Chart: Oncology: The Race Is On In HRPC; Sponsors Of Niche Oncologics Struggle
Executive Summary
Sanofi-Aventis expects to complete a rolling NDA submission for its "home grown" novel taxoid Jevtana (cabazitaxel) by the end of the first quarter, Sanofi-Aventis Global Operations President Hanspeter Spek told a Feb. 10 earning call.
You may also be interested in...
Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
Rival Medivation has a "Plan B" for Phase III if Sanofi-Aventis' cabazitaxel emerges as new standard of care as expected.
Dendreon’s Therapeutic Vaccine Provenge Gets “Complete Response” From FDA
FDA is requesting additional clinical data to support the efficacy of Dendreon’s BLA.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011